Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 11, 2023

Dose-Limiting Pulmonary Toxicity With Concurrent Ipilimumab and Chemoradiotherapy Followed by Nivolumab for Stage III Unresectable NSCLC

International Journal of Radiation Oncology, Biology, Physics


Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Radiation Oncology, Biology, Physics
Dose Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Int. J. Radiat. Oncol. Biol. Phys 2023 Jan 17;[EPub Ahead of Print], CL Liveringhouse, K Latifi, AG Asous, NB Lam, SA Rosenberg, TJ Dilling, GV MacMillan, AA Chiappori, EB Haura, B Creelan, JE Gray, T Tanvetyanon, MR Shafique, AN Saltos, AA Weiner, J Clarke, CR Kelsey, S Kim, JJ Caudell, TA Rose, JR Conejo-Garcia, J Li, MJ Schell, SJ Antonia, BA Perez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading